Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.64 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.61 |
| ▸ | PI4KA | P42356 | 2/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561516 | 1.00 | PRMT5 (0.64) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL561515 | 1.00 | PRMT5 (0.64) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL17359784 | 0.93 | PRMT5 (0.59) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL31652766 | 0.93 | PRMT5 (0.59) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL31652943 | 0.93 | PRMT5 (0.59) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL12170653 | 0.88 | ADORA3 (0.56) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL17445618 | 0.86 | ADORA3 (0.55) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL2318607 | 0.85 | PRMT5 (0.65) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL14946260 | 0.85 | PRMT5 (0.65) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL6426564 | 0.85 | PRMT5 (0.65) | PRMT5WDR77ADORA3ADORA2API4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024565-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-20180237467-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-20170088577-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-30 | — | — | US | disclosed |
| EP-2332952-B1 | Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections | IDENIX PHARMACEUTICALS INC (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2799442-A1 | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections | IDENIX Pharmaceuticals, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140213540-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140113880-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| EP-1523489-B1 | MODIFIED 2' AND 3' -NUCLEOSIDE PRODUGS FOR TREATING FLAVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8648054-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648054-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2014-02-11 | — | — | US | disclosed |
| US-20070027104-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-7138376-B2 | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides | IDENIX PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1435974-A4 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS USING 4'-MODIFIED NUCLEOSIDES | IDENIX CAYMAN LTD (KY) | 2006-09-06 | — | — | EP | disclosed |
| EP-1523489-A2 | MODIFIED 2' AND 3' -NUCLEOSIDE PRODUGS FOR TREATING FLAVIRIDAE INFECTIONS | Idenix (Cayman) Limited (KY) | 2005-04-20 | — | — | EP | disclosed |
| US-6784166-B2 | FOR THE TREATMENT OF DISEASES MEDIATED BY THE HEPATITIS C VIRUS | SYNTEX (U.S.A.) LLC | 2004-08-31 | — | — | US | disclosed |
| EP-1435974-A2 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS USING 4'-MODIFIED NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004002999-A2 | MODIFIED 2' AND 3' -NUCLEOSIDE PRODUGS FOR TREATING FLAVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| US-20040006007-A1 | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides | IDENIX PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20040006002-A1 | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside | SOMMADOSSI JEAN-PIERRE (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003026589-A2 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS USING 4'-MODIFIED NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213540-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, SLC29A2 | PRMT5 1953/4885WDR77 4654/4885ADORA3 132/4885 |
| US-20040006007-A1 | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides | PNP, MTAP, NT5C3B | PRMT5 3057/4885WDR77 1232/4885ADORA3 167/4885 |
| US-20140113880-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, SLC29A2 | PRMT5 1953/4885WDR77 4654/4885ADORA3 132/4885 |
| US-20180237467-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, UGT2B7 | PRMT5 2077/4885WDR77 4599/4885ADORA3 178/4885 |
| US-20070027104-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, UGT1A3, SLC29A2 | PRMT5 1953/4885WDR77 4654/4885ADORA3 132/4885 |
| US-20040006002-A1 | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside | PNP, MTAP, NT5C3B | PRMT5 2235/4885WDR77 2010/4885ADORA3 784/4885 |
| US-20170088577-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, UGT2B7 | PRMT5 2077/4885WDR77 4599/4885ADORA3 178/4885 |
| US-20210024565-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, SLC29A2 | PRMT5 1953/4885WDR77 4654/4885ADORA3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.